[1] P. Pahuja, S. Arora, and P. Pawar, “Ocular drug delivery system: a reference to natural polymers,†Expert Opinion on Drug Delivery, vol. 9, no. 7, pp. 837–861, 2012.
[2] S. Nisha and K. Deepak, “An insight to ophthalmic drug deliv-ery system,†International Journal of Pharmaceutical Studies Research, vol. 3, no. 2, pp. 9–13, 2012.
[3] R. Gaudana, J. Jwala, S. H. S. Boddu, and A. K. Mitra, “Recent perspectives in ocular drug delivery,†Pharmaceutical Research, vol. 26, no. 5, pp. 1197–1216, 2009.
[4] A. Rajasekaran, K. S. G. A. Kumaran, J. P. Preetha, and K. Karthika, “A comparative review on conventional and advanced ocular drug delivery formulations,†International Journal of PharmTech Research, vol. 2, no. 1, pp. 668–674, 2010.
[5] P. Tangri and S. Khurana, “Basics of ocular drug delivery systems,†International Journal of Research in Pharmaceutical and Biomedical Sciences, vol. 2, no. 4, pp. 1541–1552, 2011.
[6] International Conference on Harmonization, “Stability testing of new drug substances and products Q1A (R2),†Federal Register, vol. 68, no. 225, pp. 65717–65718, 2003.
[7] Polish Pharmacopoeia, vol. 8, part 1, The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland, 2008.
[8] K. S. Rathore and R. K. Nema, “An insight into ophthalmic drug delivery system,†International Journal of Pharmaceutical Sciences and Drug Research, vol. 1, no. 1, pp. 1–5, 2009.
[9] “The International Pharmacopoeia,†4th Edition, 2013, http://apps.who.int/phint/en/p/about/
[10] Jitendra, P. K. Sharma, A. Banik, and S. Dixit, “A new trend: ocular drug delivery system,†An International Journal of Phar- maceutical Sciences, vol. 2, no. 3, pp. 1–25, 2011.
[11] M. Yamaguchi, S.-I. Yasueda, A. Isowaki et al., “Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate,†International Journal of Pharma-ceutics, vol. 301, no. 1-2, pp. 121–128, 2005.
[12] Y. Kapoor and A. Chauhan, “Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant- laden p-HEMA hydrogels,†International Journal of Pharmaceutics, vol. 361, no. 1-2, pp. 222–229, 2008.
[13] J. Shen, L. Gan, C. Zhu et al., “Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect,†International Journal of Pharmaceutics, vol. 412, no. 1-2, pp. 115–122, 2011.
[14] R. Shaikh, T. Raj Singh, M. Garland, A. Woolfson, and R. Donnelly, “Mucoadhesive drug delivery systems,†Journal of Pharmacy and Bioallied Sciences, vol. 3, no. 1, pp. 89–100, 2011
[15] T. J¨arvinen and K. J¨arvinen, “Prodrugs for improved ocular drug delivery,†Advanced Drug Delivery Reviews, vol. 19, no. 2, pp. 203–224, 1996.
[16] T. Loftsson and E. Stef´ansson, “Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye,†Acta Ophthalmologica Scandinavica, vol. 80, no. 2, pp. 144– 150, 200
[17] H. J. Jung, M. Abou-Jaoude, B. E. Carbia, C. Plummer, and A. Chauhan, “Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses,†Journal of Controlled Release, vol. 165, no. 1, pp. 82–89, 2013.
[18] A. Hui, A. Boone, and L. Jones, “Uptake and release of ciprofloxacin-HCl from conventional and silicone hydrogel contact lens materials,†Eye & Contact Lens, vol. 34, no. 5, pp. 266–271, 2008
[19] A. Boone, A. Hui, and L. Jones, “Uptake and release of dexamethasone phosphate from silicone hydrogel and group I, II, and IV hydrogel contact lenses,†Eye and Contact Lens, vol. 35, no. 5, pp. 260–267, 2009.
[20] C.-C. Peng and A. Chauhan, “Extended cyclosporine deliv- ery by silicone-hydrogel contact lenses,†Journal of Controlled Release, vol. 154, no. 3, pp. 267–274, 2011.
[21] M. H. Aburahma and A. A. Mahmoud, “Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: prepara- tion and in vitro/in vivo evaluation,†AAPS PharmSciTech, vol. 12, no. 4, pp. 1335–1347, 2011
[22] P. Goudanavar, N. Ambhore, D. Hiremath, and R. Udupi, “Comparative evaluation of polymer combination in the design of brimonidine tartrate ocular inserts,†Indian Drugs, vol. 49, no. 7, pp. 30–35, 2012.
[23] N. Kumar and S. Sharma, “Design, formulation and evaluation of sustained ophthalmic delivery of ciprofloxacin from ocular inserts,†Research Journal of Pharmacy and Technology, vol. 6, no. 3, pp. 285–286, 2013.
[24] A. S. Mundada and B. K. Shrikhande, “Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride,†Drug Developmand Industrial Pharmacy, vol. 32, no. 4, pp. 443–448, 2006
[25] S. S. Patil, D. Hiremath, P. Reddy, and K. K. Sirse, “Design and evaluation of ocular inserts of moxifloxacin hydrochloride,†International Journal of Pharmaceutical Research, vol. 4, no. 3, pp. 42–48, 2012.
[26] A. S. Mundada and B. K. Shrikhande, “Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert,†Current Eye Research, vol. 33, no. 5-6, pp. 469–475, 2008.
[27] G. Venkata Ratnam, S. Madhavi, and P. Rajesh, “Ocular drug delivery: an update review,†International Journal of Pharmacy and Biological Sciences, vol. 1, no. 4, pp. 437–446, 2011.
[28] R. Shivhare, A. Pathak, N. Shrivastava, C. Singh, G. Tiwari, and R. Goyal, “An update review on novel advanced ocular drug delivery system,†World Journal of Pharmacy and Pharmaceutical Sciences, vol. 1, no. 2, pp. 545–568, 2012
[29] Y. F. Maichuk, “Ophthalmic drug inserts,†Investigative Ophthal- mology, vol. 14, no. 2, pp. 87–90, 1975.
[30] D. Karthikeyan, M. Bhowmick, V. P. Pandey et al., “The concept of ocular inserts as drug delivery systems: an overview,†Asian Journal of Pharmaceutics, vol. 2, no. 4, pp. 192–200,
